Nanobiotix SA

Voting Rights and Shares Capital of the Company

08 أغسطس 2024 16:15:00 بحسب Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

09 يوليو 2024 16:15:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024

12 يونيو 2024 16:15:00 بحسب Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

11 يونيو 2024 16:15:00 بحسب Nasdaq GlobeNewswire

Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy

02 يونيو 2024 10:00:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call

28 مايو 2024 16:15:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX to Present at the Jefferies Global Healthcare Conference

23 مايو 2024 16:15:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update

22 مايو 2024 02:00:00 بحسب Nasdaq GlobeNewswire

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

21 مايو 2024 16:15:00 بحسب Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

16 مايو 2024 16:15:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024

15 مايو 2024 16:15:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer

14 مايو 2024 16:15:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results

24 أبريل 2024 16:40:39 بحسب Nasdaq GlobeNewswire

NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024

17 أبريل 2024 16:15:00 بحسب Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

10 أبريل 2024 16:15:00 بحسب Nasdaq GlobeNewswire

Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation

02 أبريل 2024 16:15:00 بحسب Nasdaq GlobeNewswire

Nanobiotix to Present at Upcoming Investor Conferences in March

06 مارس 2024 16:15:00 بحسب Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

13 فبراير 2024 16:15:00 بحسب Nasdaq GlobeNewswire

Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference

31 يناير 2024 16:15:00 بحسب Nasdaq GlobeNewswire

Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study

29 يناير 2024 16:15:00 بحسب Nasdaq GlobeNewswire